- Home
- NEXM vs CGEN Comparison
NEXM vs CGEN Comparison
Compare NEXM & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NEXM | CGEN |
|---|---|---|
| Founded | N/A | 1993 |
| Country | Canada | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.5M | 148.7M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | NEXM | CGEN |
|---|---|---|
| Price | $3.28 | $1.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 109.1K | ★ 295.0K |
| Earning Date | 03-20-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $6,903,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $164.92 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.31 | $1.13 |
| 52 Week High | $10.35 | $2.38 |
Technical Indicators
Market Signals| Indicator | NEXM | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 37.99 | 44.44 |
| Support Level | $3.35 | $1.63 |
| Resistance Level | $3.69 | $1.82 |
| Average True Range (ATR) | 0.30 | 0.09 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 12.26 | 25.56 |
Price Performance
Historical ComparisonAbout NEXM NexMetals Mining Corp.
NexMetals Mining Corp is a mineral exploration and development company focused on discovering and advancing high-quality copper-nickel-cobalt-platinum element metals (Cu- Cu-Ni-Co-PGE) resources. The group prioritizes projects in stable, mining-friendly jurisdictions with supportive foreign investment and rule-of-law standards. Its projects are Botswana and Canada.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.